These drugs block selected enzymes that control cell division or gene reading. The enzyme, exposure and measured outcome matter; slower growth can mean a pause rather than cell death.
Cyclin-dependent kinase inhibitors affect selected enzymes involved in cell-cycle progression, transcription or both. The kinase, regulatory partners, compound profile and exposure determine which functions are being tested.
A change in substrate phosphorylation, an RNA signal, reversible growth arrest, cell death, marrow protection and a clinical cancer outcome require different measurements. Clinical evidence remains specific to the product, disease, regimen and endpoint.
Shares CDK2, CDK4/6, CDK4/6 inhibitors.
Shares CDK4/6, CDK4/6 inhibitors.
Shares CDK4/6, CDK4/6 inhibitors.
Shares CDK4/6, CDK4/6 inhibitors.
Shares CDK4/6, CDK4/6 inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/